WO2009116076A3 - Préparations ophtalmiques stériles et leur procédé de préparation - Google Patents

Préparations ophtalmiques stériles et leur procédé de préparation Download PDF

Info

Publication number
WO2009116076A3
WO2009116076A3 PCT/IN2009/000113 IN2009000113W WO2009116076A3 WO 2009116076 A3 WO2009116076 A3 WO 2009116076A3 IN 2009000113 W IN2009000113 W IN 2009000113W WO 2009116076 A3 WO2009116076 A3 WO 2009116076A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation containing
ophthalmic preparation
pyridinol derivative
pyridinol
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000113
Other languages
English (en)
Other versions
WO2009116076A2 (fr
Inventor
Ashok Vasantray Vyas
Ravindra Tukaram Jadhav
Subhash Trimbak Phad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
M J Biopharm Pvtltd
Original Assignee
M J Biopharm Pvtltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M J Biopharm Pvtltd filed Critical M J Biopharm Pvtltd
Priority to EP09721331A priority Critical patent/EP2265252A2/fr
Priority to CN2009801134833A priority patent/CN102006872A/zh
Priority to EA201001326A priority patent/EA201001326A1/ru
Publication of WO2009116076A2 publication Critical patent/WO2009116076A2/fr
Publication of WO2009116076A3 publication Critical patent/WO2009116076A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition ophtalmique comprenant 3-hydroxy 2,4,6 triméthylpyridine, des sels pharmaceutiquement acceptables, des esters, des dérivés et des polymorphes de celle-ci pour traiter une hémorragie intraoculaire et la dégénérescence maculaire.
PCT/IN2009/000113 2008-02-19 2009-02-19 Préparations ophtalmiques stériles et leur procédé de préparation Ceased WO2009116076A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09721331A EP2265252A2 (fr) 2008-02-19 2009-02-19 Preparation ophtalmique contenant un derive pypidinole
CN2009801134833A CN102006872A (zh) 2008-02-19 2009-02-19 含有吡啶酚衍生物的眼科制剂
EA201001326A EA201001326A1 (ru) 2008-02-19 2009-02-19 Стерильные офтальмологические композиции и способ их получения

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN355MU2008 2008-02-19
IN355/MUM/2008 2008-02-19

Publications (2)

Publication Number Publication Date
WO2009116076A2 WO2009116076A2 (fr) 2009-09-24
WO2009116076A3 true WO2009116076A3 (fr) 2010-01-07

Family

ID=41091336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000113 Ceased WO2009116076A2 (fr) 2008-02-19 2009-02-19 Préparations ophtalmiques stériles et leur procédé de préparation

Country Status (4)

Country Link
EP (1) EP2265252A2 (fr)
CN (1) CN102006872A (fr)
EA (1) EA201001326A1 (fr)
WO (1) WO2009116076A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2252265A4 (fr) * 2008-02-19 2011-04-20 Marvel Lifesciences Ltd Préparations injectables et leur procédé de préparation
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
CN102526282A (zh) * 2012-03-11 2012-07-04 周洁 一种降低糖尿病眼病的眼压的外用保健品
EP3530262B1 (fr) 2018-02-27 2026-01-14 The Procter & Gamble Company Compositions de soins personnels et utilisations
CN109030474A (zh) * 2018-06-13 2018-12-18 迦娜生物科技（武汉）有限公司 一种脂质自由基尿液检测试剂及其应用
EP3842041B1 (fr) * 2018-08-17 2025-05-21 Nibec Co., Ltd. Composition pour le traitement et la prévention de la gingivo-périodontite ou de la péri-implantite et brosse interdentaire revêtue de celle-ci
RU2703306C1 (ru) * 2018-09-27 2019-10-16 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ повышения зрительных функций при эндовитреальной хирургии регматогенной отслойки сетчатки
EP4176881A4 (fr) * 2020-07-30 2024-07-31 Rohto Pharmaceutical Co., Ltd. Composition aqueuse

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614857A1 (fr) * 2004-05-12 2007-02-15 Marvel Lifesciences Limited Substance possedant un effet antioxydant, geroprotecteur et anti-ischemique et procede de fabrication correspondant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2614857A1 (fr) * 2004-05-12 2007-02-15 Marvel Lifesciences Limited Substance possedant un effet antioxydant, geroprotecteur et anti-ischemique et procede de fabrication correspondant

Also Published As

Publication number Publication date
WO2009116076A2 (fr) 2009-09-24
EA201001326A1 (ru) 2011-04-29
CN102006872A (zh) 2011-04-06
EP2265252A2 (fr) 2010-12-29

Similar Documents

Publication Publication Date Title
WO2010048332A3 (fr) Composés de traitement de maladies et troubles ophtalmiques
WO2008140051A1 (fr) Agent prophylactique ou thérapeutique destiné à une maladie oculaire postérieure comprenant un agoniste qui n'est pas dérivé de l'ergot de seigle sélectif du récepteur d2 en tant que principe actif
WO2007035473A3 (fr) Dispositif d'administration pharmaceutique et procede permettant de conferer un traitement oculaire
WO2005079774A3 (fr) Gestion de troubles ophtalmologiques, notamment la degenerescence maculaire
WO2009035673A8 (fr) Compositions et procédés de traitement de la dégénérescence maculaire
EP2371853A3 (fr) Dérivés d'insuline ou ses sels pharmaceutiquement acceptables, composition pharmaceutique, utilisation du dérivé d'insuline et son sel pharmaceutiquement acceptable et procédé de traitement
IL212113A (en) A device for the implantation of a drug for glaucoma treatment
WO2009005794A3 (fr) Dérivés d'alcynylphényle pour traiter les maladies et les affections ophtalmiques
WO2009066315A3 (fr) Compositions à libération prolongée de trimétazidine et procédé de préparation
WO2007136759A3 (fr) Procédé de traitement et de prévention de troubles oculaires
WO2008015517A3 (fr) Agonistes de ep2
WO2005097135A3 (fr) Utilisation de derives de 9h-purine-2,6-diamine dans le traitement de maladies proliferantes et nouveaux derives de 9h-purine-2,6-diamine
WO2010028088A3 (fr) Composants à liaison soufre pour le traitement de maladies et de troubles ophtalmiques
WO2009023710A3 (fr) Extrait de houblon enrichi en xanthohumol
WO2007098122A3 (fr) Méthodes pour traiter une dégénérescence maculaire et des troubles apparentés de l'œil
WO2014143754A3 (fr) Implant intraoculaire contenant de la prostamide
WO2008020032A8 (fr) Utilisation de dérivés de 2,5-dihydroxybenzène pour le traitement de maladies oculaires
WO2007019503A3 (fr) Gestion de troubles ophtalmologiques tels que la degenerescence maculaire
WO2007093365A3 (fr) Nouvelles arylthiénopyrimidinones à substitution aminoalcool, leur procédé de préparation et leur utilisation comme médicaments
NZ605022A (en) Heterocyclic compounds, their preparation and their therapeutic application
WO2008150085A3 (fr) Dérivés de 3',4',5-triméthoxy flavone en tant que stimulant de sécrétion de mucus, procédé correspondant, et composition pharmaceutique comportant lesdits dérivés
WO2006062731A8 (fr) Utilisation de la phenanthroline et de ses derives pour abaisser la tension intraoculaire d'un oeil affecte
WO2009116078A3 (fr) Formulations de dosage orales et leur procédé de préparation
EA201001326A1 (ru) Стерильные офтальмологические композиции и способ их получения
WO2005107711A3 (fr) Procede et composition permettant de traiter la rhinite

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980113483.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09721331

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009721331

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201001326

Country of ref document: EA